Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Mind Medicine (MindMed) Inc MNMD

Alternate Symbol(s):  N.MMED.WS | N.MMED.WA | N.MMED.WR | N.MMED

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).


NDAQ:MNMD - Post by User

Bullboard Posts
Comment by stanleyon Dec 11, 2010 10:09am
332 Views
Post# 17833373

RE: What Is up with Brigus? Hot Potato Syndrome

RE: What Is up with Brigus? Hot Potato SyndromeJosameyer:

[S] While the HFT's could be playing "hot potato" with BRD, here is an excellent article from Canada Stockwatch that explains why HFT does not represent a good long term value for the average/retail shareholder.  i.e. This NOT a level playing field.  Canada Stockwatch allows subscribers to see what brokers allow HFT. I hope that they have a KYC.  On the bright side, we are seeing a PPS appreciation as we go into the Canadian tax loss selling season. Always interesting to see who is on what side of the buy/sell list:
----------------------------------------------------------------

High Frequency Traders Play Hot Potato


2010-12-06 20:22 AT - Street Wire


by Stockwatch Business Reporter

<snip>

According to an article on the Finextra website, Europeanregulators will publish new trading rules, MiFID II, this week. Underthe new rules, high frequency traders (HFT's) will have to explain how theydesign their computer algorithms, and how they work. Also, HFTs tradingover a certain volume will have to be authorized investment firms withrisk controls.

A fast trader can submit five trades a minute,whereas an HFT can submit 60 million trades a minute, according to aReuters report. That means on a regular trading day of 6.5 hours, or 390minutes, a fast trader could make about 78 trades, while an HFT couldmake 23.4 billion. To increase profits HFTs are constantly trying totrim milliseconds off trading time. There are 300 to 400 milliseconds inthe time it takes to blink.

One TSX-V-listed company, SeafieldResources Ltd., is exhibiting what the United States Securities andExchange Commission calls the "hot potato volume effect." This is whenHFTs buy or sell to one other very rapidly. Eventually the stock willland in the hands of a fundamental investor, someone willing to hold thestock for more than a few seconds. On Friday, Dec. 3, Seafield rose 34cents to 57 cents on 91.35 million shares. On Monday it continued itsunnatural ways, adding six cents to 63 cents on 45.48 million shares.Opponents to HFT say the hot potato effect helps order execution butdoes not add true liquidity to the market. U.S. Commodity FuturesTrading Commission chairman Gary Gensler has said repeatedly that "volume does not equal liquidity." Themis Trading's Joe Saluzzi agrees;he says playing hot potato is similar to circular trading, in which agroup of traders work together trading a stock to make it look like thestock is on its way up before dumping it.

SCARY STUFF, Not for the faint of heart

GLTAL-GLAP

Cheers

Stanley

Bullboard Posts